Morgan Stanley analyst Judah Frommer raised the firm’s price target on Trevi Therapeutics (TRVI) to $19 from $18 and keeps an Overweight rating on the shares after the company provided its third quarter update, noting incremental progress on the safety side if its Haduvio program and successful presentations at recent scientific meetings.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics price target raised to $24 from $23 at Oppenheimer
- Trevi Therapeutics Positioned for Market Leadership with Promising Haduvio Developments and Strong Financial Health
- Trevi Therapeutics price target raised to $21 from $11 at Clear Street
- Trevi Therapeutics: Strategic Clinical Trials and Promising Haduvio Drive Buy Rating
- Trevi Therapeutics Reports Q3 2025 Financials and Updates